Product details
Background：Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
• Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial., PMID:33290737
• Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism., PMID:35699915
• The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market., PMID:37044200
• Dose tailoring of dabigatran etexilate: obvious or excessive?, PMID:25994994
• A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects., PMID:31652461
• Idarucizumab for Dabigatran Reversal – Full Cohort Analysis., PMID:28693366
• Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation., PMID:28185082
• Direct oral anticoagulants: evidence and unresolved issues., PMID:33248499
• Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta., PMID:24807346
• The discovery of dabigatran etexilate for the treatment of venous thrombosis., PMID:27159158
